S&P Futures
4,132.25-0.50(-0.01%)Dow Futures
33,540.00-30.00(-0.09%)Nasdaq Futures
13,966.00-9.75(-0.07%)
NeoGenomics, Inc. (NEO)
49.52 +0.01 (0.02%)
After hours: 7:26PM EDT
- ACCESSWIRE
NeoGenomics to Participate in the 20th Annual Needham Virtual Healthcare Conference
MYERS, FL / ACCESSWIRE / April 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the 20th Annual Needham Virtual Healthcare Conference 2021, on Thursday, April 15, 2021 at 11:00am ET.
- ACCESSWIRE
NeoGenomics Schedules its First Quarter 2021 Earnings Release for May 5, 2021
FT MYERS, FL / ACCESSWIRE / April 7, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its first quarter 2021, financial results on Wednesday, May 5, 2021.
- Zacks
Strength Seen in NeoGenomics (NEO): Can Its 7.9% Jump Turn into More Strength?
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
